Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 50 of 109 entries
View as:
Phase: N/A
Priority: Normal
Start: 10/13/17
End: 10/13/23
Due: 10/13/24
Phase: N/A
Priority: Normal
Start: 07/31/25
End: 01/31/29
Due: 01/31/30
Phase: N/A
Priority: Normal
Start: 06/30/14
End: 03/31/16
Due: 03/31/17
Phase: N/A
Priority: Normal
Start: 12/31/14
End: 03/31/20
Due: 03/31/21
Phase: N/A
Priority: Normal
Start: 11/21/24
End: 10/15/27
Due: 10/15/28
Phase: N/A
Priority: Normal
Start: 01/31/16
End: 12/31/17
Due: 12/31/18
Phase: N/A
Priority: Normal
Start: 05/15/25
End: 09/15/28
Due: 09/15/29
Phase: N/A
Priority: Normal
Start: 12/31/08
End: 07/31/15
Due: 07/31/16
Phase: N/A
Priority: Normal
Start: 11/07/18
End: 05/31/27
Due: 05/31/28
Phase: N/A
Priority: Normal
Start: 02/29/12
End: 05/31/17
Due: 05/31/18
Relation Between Safety Endpoints and Everolimus Trough Blood Level in Advanced Renal Cell Carcinoma
Phase: N/A
Priority: Normal
Start: 04/30/12
End: 12/31/15
Due: 12/31/16
Phase: N/A
Priority: Normal
Start: 04/30/10
End: 01/31/13
Due: 01/31/14
Phase: N/A
Priority: Normal
Start: 05/29/18
End: 12/11/18
Due: 12/11/19
Phase: N/A
Priority: Normal
Start: 01/31/13
End: 02/28/15
Due: 02/28/16
Phase: N/A
Priority: Normal
Start: 05/31/13
End: 11/30/15
Due: 11/30/16
Phase: N/A
Priority: Normal
Start: 09/30/09
End: 11/30/11
Due: 11/30/12
Phase: N/A
Priority: Normal
Start: 10/31/08
End: 06/30/13
Due: 06/30/14
Phase: N/A
Priority: Normal
Start: 12/24/20
End: 11/16/22
Due: 11/16/23
Phase: N/A
Priority: Normal
Start: 05/17/23
End: 07/31/25
Due: 07/31/26
Phase: N/A
Priority: Normal
Start: 09/17/18
End: 11/15/18
Due: 11/15/19
Phase: N/A
Priority: Normal
Start: 01/09/23
End: 12/31/26
Due: 12/31/27
Phase: N/A
Priority: Normal
Start: 12/31/14
End: 07/31/16
Due: 07/31/17
Phase: N/A
Priority: Normal
Start: 05/31/16
End: 03/28/19
Due: 03/28/20
Phase: N/A
Priority: Normal
Start: 03/01/25
End: 03/01/34
Due: 03/01/35
Phase: N/A
Priority: Normal
Start: 02/29/12
End: 03/31/16
Due: 03/31/17